QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Teprotumumab, Thyroid Eye Disease and Product Pharmacovigilance

Test your understanding of the concepts covered by Teprotumumab: IGF-1 receptor biology, thyroid eye disease, and product pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which administration and observation practice is most consistent with the article’s safety framework?

Give one fixed dose to all patients and discharge immediately after infusion Use a 10 mg/kg loading dose followed by 20 mg/kg every three weeks for seven further infusions, with observation during infusion and for 90 minutes afterward Give 20 mg/kg daily until proptosis resolves Administer the treatment subcutaneously once monthly without infusion monitoring

Question 2 of 10 Which data element is especially important for biological product traceability in a suspected adverse reaction report?

The patient’s preferred brand of eyeglasses The exact product name and batch or lot number Only the indication, without exposure dates The prescriber’s specialty, without the administered dose

Question 3 of 10 Which patient factor most directly increases the need for proactive glucose assessment and monitoring during teprotumumab treatment?

A history of stable seasonal allergic rhinitis Diabetes or impaired glucose tolerance, particularly with concurrent glucocorticoid exposure A history of inactive strabismus alone Use of corrective eyeglasses

Question 4 of 10 Why is baseline and serial audiometry particularly important during teprotumumab therapy?

Hearing impairment always causes immediate and unmistakable symptoms Audiometry is needed only to document manufacturing defects Objective threshold changes may precede patient complaints and provide a comparator for longitudinal assessment Audiometry determines whether the patient has active thyroid disease

Question 5 of 10 Which statement about cross-trial comparison with another IGF-1R antibody is most appropriate?

Different infusion numbers alone prove which antibody is safer Results from separate studies can establish superiority if both products target IGF-1R Cross-trial comparisons cannot establish comparative efficacy or safety without an appropriate comparative study A shorter regimen necessarily means lower cumulative risk and equal benefit

Question 6 of 10 Which case detail would most directly improve evaluation of suspected teprotumumab-associated hyperglycaemia?

Only the patient’s final eye colour Baseline HbA1c and glucose, serial values, diabetes treatment, steroid exposure, symptoms, ketones when indicated, and treatment changes The patient’s preferred infusion-room location A single glucose value with no timing or baseline information

Question 7 of 10 Which statement most accurately describes the significance of the absence of a US product-specific REMS for teprotumumab?

It means the product has no important safety risks It means routine pharmacovigilance and prescribing information are not required It indicates that the FDA review concluded a REMS was not required, while ordinary safety obligations and monitoring remain necessary It requires European educational materials to be implemented unchanged in the United States

Question 8 of 10 Which approach provides the strongest causality assessment for a new audiometric threshold shift after teprotumumab?

Assume causality solely because the event occurred after treatment Exclude causality because the patient had a history of noise exposure Integrate timing, objective audiometry, dechallenge or follow-up, alternative causes, concomitant ototoxic medicines, and any rechallenge information Rely only on whether the patient reported tinnitus

Question 9 of 10 What conclusion is best supported by evidence in patients with long-duration, low-activity TED?

Only actively inflamed disease can respond to IGF-1R inhibition A modifiable component may remain after obvious inflammation subsides, although fixed fibrosis and residual anatomy may persist All chronic diplopia and lid abnormalities should resolve without surgery The chronic-disease study proves that retreatment is routinely required

Question 10 of 10 What is the most defensible interpretation of teprotumumab’s mechanism in TED based on the article?

The complete molecular mechanism is established and proves that IGF-1R autoantibodies cause all TED The treatment directly cures the underlying Graves-related autoimmune tendency IGF-1R inhibition can reduce disease-relevant orbital outputs, but the precise human mechanism and role of IGF-1R-directed antibodies remain incompletely characterized Clinical efficacy cannot be accepted because the mechanism is not fully characterized

Knowledge Assessment: Teprotumumab, Thyroid Eye Disease and Product Pharmacovigilance

Cookie Settings